PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer

Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release

Diverse CD28-binding antibodies for costimulatory T-cell engager development

Development of PSMA x CD3 T-cell engagers using an integrated, functional approach 

Target-dependent considerations for the design of bispecific T-cell engagers 

Functional and specific T-cell engagers for a peptide-MHC tumor target 

Discovery of diverse GPCR-targeted antibodies using integrated technologies

A rational approach for selecting CD3-binding antibodies for T-cell engager development

Targeting intracellular tumor antigens to fight cancer: discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC

Identifying T-cell engagers with optimal potency and cytokine-release profiles with a diverse panel of CD3-binding antibodies